35.10
2.12%
0.73
Guardant Health Inc stock is traded at $35.10, with a volume of 994.07K.
It is up +2.12% in the last 24 hours and up +71.14% over the past month.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$34.37
Open:
$35.05
24h Volume:
994.07K
Relative Volume:
0.48
Market Cap:
$4.32B
Revenue:
$643.81M
Net Income/Loss:
$-490.76M
P/E Ratio:
-8.6453
EPS:
-4.06
Net Cash Flow:
$-299.27M
1W Performance:
+14.41%
1M Performance:
+71.14%
6M Performance:
+37.54%
1Y Performance:
+43.85%
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
35.10 | 4.32B | 643.81M | -490.76M | -299.27M | -4.06 |
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
Jun-03-24 | Resumed | Jefferies | Buy |
Apr-24-24 | Resumed | Craig Hallum | Buy |
Dec-14-23 | Initiated | Guggenheim | Neutral |
Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Sep-28-23 | Initiated | Bernstein | Outperform |
Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
Jul-05-23 | Resumed | JP Morgan | Overweight |
May-26-23 | Upgrade | Citigroup | Neutral → Buy |
May-05-23 | Initiated | UBS | Buy |
Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
Oct-19-22 | Initiated | Craig Hallum | Buy |
Oct-06-22 | Initiated | Stephens | Overweight |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Jun-03-22 | Initiated | Piper Sandler | Overweight |
Apr-28-22 | Resumed | BTIG Research | Buy |
Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
Feb-24-22 | Reiterated | Citigroup | Buy |
Feb-24-22 | Reiterated | Cowen | Outperform |
Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
Feb-24-22 | Reiterated | SVB Leerink | Outperform |
Feb-24-22 | Reiterated | Stifel | Buy |
Feb-24-22 | Reiterated | Wells Fargo | Overweight |
Oct-15-21 | Resumed | Cowen | Outperform |
Jun-15-21 | Initiated | Raymond James | Mkt Perform |
Jun-03-21 | Initiated | Goldman | Buy |
May-25-21 | Initiated | Wells Fargo | Overweight |
Jan-11-21 | Initiated | Stifel | Buy |
Sep-09-20 | Initiated | Morgan Stanley | Overweight |
Jun-12-20 | Initiated | BTIG Research | Buy |
Feb-21-20 | Initiated | Guggenheim | Buy |
Jan-07-20 | Initiated | Citigroup | Buy |
Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
Apr-16-19 | Initiated | Canaccord Genuity | Buy |
Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
Oct-29-18 | Initiated | BofA/Merrill | Neutral |
Oct-29-18 | Initiated | JP Morgan | Overweight |
Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
KAS Team Wins $292.5 Million In Jury Trial of Guardant Health v. Natera - Morningstar
Advantage Alpha Capital Partners LP Buys New Position in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Guardant Health, Inc. (GH) Stock Price, News, Quote & History - Yahoo Finance
Jury Awards Guardant Health $292.5M in False-Advertising Lawsuit Against Natera - MarketWatch
Guardant says jury unanimously found in favor of company in Natera suit - TipRanks
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims - MSN
Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update) - MSN
Guardant Health Wins Historic $292.5M False Advertising Verdict Against Natera | NTRA Stock News - StockTitan
Natera Plans Appeal After Guardant Health Lawsuit Verdict, Defends Signatera Test Leadership | NTRA Stock News - StockTitan
BREAKING: Jury Finds Natera Owes Guardant $292.5M In False Ad Suit - Law360
Landscape Capital Management L.L.C. Acquires Shares of 31,448 Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health, Inc. (GH): Among the Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
(GH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Natera's Conduct 'Despicable,' Guardant Says As Trial Wraps - Law360
Guardant Health (GH) Set To Dominate The Growing Liquid Biopsy Market - Insider Monkey
Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
GH (Guardant Health) Operating Cash Flow per Share : $-2.10 (TTM As of Sep. 2024) - GuruFocus.com
Guardant Health Stock Sees RS Rating Jump To 83 - Yahoo! Voices
Guardant Health: Focused On Future Growth, Hold - Seeking Alpha
GH (Guardant Health) Free Cash Flow per Share : $-2.26 (TTM As of Sep. 2024) - GuruFocus.com
Guardant Health, Inc. (NASDAQ:GH) Q3 2024 Earnings Call Transcript - MSN
Guardant Health CIO Kumud Kalia sells $204,722 in stock - Investing.com India
Guardant Health Inc (GH) Shares Up 5.46% on Nov 19 - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Grows Stake in Guardant Health, Inc. (NASDAQ:GH) - MarketBeat
Guardant Health (FRA:5GH) Total Inventories : €65.1 Mil (As of Sep. 2024) - GuruFocus.com
Natera Exec Calls Guardant's Cancer Test Claims 'Dangerous' - Law360
Insider Selling: Director Meghan Joyce Sells Shares of Guardant Health Inc (GH) - GuruFocus.com
Guardant Health director Meghan Joyce sells $86,595 in stock - Investing.com
CADIAN CAPITAL MANAGEMENT, LP's Strategic Acquisition in Guardan - GuruFocus.com
Guardant Atty Accuses Natera CEO Of Dishonesty At Trial - Law360
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Baillie Gifford & Co. - MarketBeat
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market - openPR
Guardant Health Inc (GH) Stock Price Up 6.63% on Nov 13 - GuruFocus.com
Guardant CEO Says Rival's False Ads Hurt 'Beautiful Baby' - Law360
Multi-cancer Early Detection Market Next Big Thing| Major Giants Exact Sciences, AnchorDx, Guardant Health - openPR
Wellington Management Group LLP Bolsters Stake in Guardant Healt - GuruFocus.com
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher - Simply Wall St
Guardant Health, Inc. (NASDAQ:GH) Shares Bought by ARK Investment Management LLC - MarketBeat
Guardant Health Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Why Guardant Health Stock Blasted 13% Higher on Thursday - MSN
Ex-Natera VP Defends Ad Campaign Against Rival Guardant - Law360
Guardant Health (GH) Stock Surges on Strong Q3 Earnings - GuruFocus.com
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop - Yahoo! Voices
Leerink stays bullish on Guardant Health stock, citing robust growth prospects - Investing.com Canada
JPMorgan Chase & Co. Raises Guardant Health (NASDAQ:GH) Price Target to $50.00 - MarketBeat
Guardant Health (NASDAQ:GH) Shares Gap Up Following Analyst Upgrade - MarketBeat
Guardant Health (NASDAQ:GH) Price Target Raised to $36.00 at The Goldman Sachs Group - MarketBeat
Guardant Health Inc (GH) Trading 13.31% Higher on Nov 7 - GuruFocus.com
Guardant Health Inc (GH) Q3 2024 Earnings Call Highlights: Recor - GuruFocus.com
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):